@article{RiegerLissMellinghoffetal.2018,
  author    = {Rieger, C. T. and Liss, B. and Mellinghoff, S. and Buchheidt, D. and Cornely, O. A. and Egerer, G. and Heinz, W. J. and Hentrich, M. and Maschmeyer, G. and Mayer, K. and Sandherr, M. and Silling, G. and Ullmann, A. and Vehreschild, M. J. G. T. and von Lilienfeld-Toal, M. and Wolf, H. H. and Lehners, N.},
  title     = {Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)},
  series = {Annals of Oncology},
  volume    = {29},
  journal   = {Annals of Oncology},
  number    = {6},
  doi       = {10.1093/annonc/mdy117},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226196},
  pages     = {1354-1365},
  year      = {2018},
  abstract  = {Infectious complications are a significant cause of morbidity and mortality in patients with malignancies specifically when receiving anticancer treatments. Prevention of infection through vaccines is an important aspect of clinical care of cancer patients. Immunocompromising effects of the underlying disease as well as of antineoplastic therapies need to be considered when devising vaccination strategies. This guideline provides clinical recommendations on vaccine use in cancer patients including autologous stem cell transplant recipients, while allogeneic stem cell transplantation is subject of a separate guideline. The document was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) by reviewing currently available data and applying evidence-based medicine criteria.},
  language  = {en}
}
@article{NadellaMohantySharmaetal.2018,
  author    = {Nadella, Vinod and Mohanty, Aparna and Sharma, Lalita and Yellaboina, Sailu and Mollenkopf, Hans-Joachim and Mazumdar, Varadendra Balaji and Palaparthi, Ramesh and Mylavarapu, Madhavi B. and Maurya, Radheshyam and Kurukuti, Sreenivasulu and Rudel, Thomas and Prakash, Hridayesh},
  title     = {Inhibitors of Apoptosis Protein Antagonists (Smac Mimetic Compounds) Control Polarization of Macrophages during Microbial Challenge and Sterile Inflammatory Responses},
  series = {Frontiers in Immunology},
  volume    = {8},
  journal   = {Frontiers in Immunology},
  number    = {1792},
  issn      = {1664-3224},
  doi       = {10.3389/fimmu.2017.01792},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-197484},
  year      = {2018},
  abstract  = {Apoptosis is a physiological cell death process essential for development, tissue homeostasis, and for immune defense of multicellular animals. Inhibitors of apoptosis proteins (IAPs) regulate apoptosis in response to various cellular assaults. Using both genetic and pharmacological approaches we demonstrate here that the IAPs not only support opportunistic survival of intracellular human pathogens like Chlamydia pneumoniae but also control plasticity of iNOS+ M1 macrophage during the course of infection and render them refractory for immune stimulation. Treatment of Th1 primed macrophages with birinapant (IAP-specific antagonist) inhibited NO generation and relevant proteins involved in innate immune signaling. Accordingly, birinapant promoted hypoxia, angiogenesis, and tumor-induced M2 polarization of iNOS+ M1 macrophages. Interestingly, birinapant-driven changes in immune signaling were accompanied with changes in the expression of various proteins involved in the metabolism, and thus revealing the new role of IAPs in immune metabolic reprogramming in committed macrophages. Taken together, our study reveals the significance of IAP targeting approaches (Smac mimetic compounds) for the management of infectious and inflammatory diseases relying on macrophage plasticity.},
  language  = {en}
}
@article{StrobelJohswich2018,
  author    = {Strobel, Lea and Johswich, Kay O.},
  title     = {Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection},
  series = {Scientific Reports},
  volume    = {8},
  journal   = {Scientific Reports},
  number    = {10225},
  doi       = {10.1038/s41598-018-28583-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-176226},
  year      = {2018},
  abstract  = {Neisseria meningitidis (meningococcus) causes invasive diseases such as meningitis or septicaemia. Ex vivo infection of human whole blood is a valuable tool to study meningococcal virulence factors and the host innate immune responses. In order to consider effects of cellular mediators, the coagulation cascade must be inhibited to avoid clotting. There is considerable variation in the anticoagulants used among studies of N. meningitidis whole blood infections, featuring citrate, heparin or derivatives of hirudin, a polypeptide from leech saliva. Here, we compare the influence of these three different anticoagulants, and additionally Mg/EGTA, on host innate immune responses as well as on viability of N. meningitidis strains isolated from healthy carriers and disease cases, reflecting different sequence types and capsule phenotypes. We found that the anticoagulants significantly impact on cellular responses and, strain-dependently, also on bacterial survival. Hirudin does not inhibit complement and is therefore superior over the other anticoagulants; indeed hirudin-plasma most closely reflects the characteristics of serum during N. meningitidis infection. We further demonstrate the impact of heparin on complement activation on N. meningitidis and its consequences on meningococcal survival in immune sera, which appears to be independent of the heparin binding antigens Opc and NHBA.},
  language  = {en}
}